about
Young women's experiences with complementary therapies during cancer described through illness blogsThe unique supportive care needs of a mother with acute myeloid leukemia during treatment.Management of Cancer Related Distress in Patients with a Hematological Malignancy.Management of febrile neutropenia in a patient with acute leukemia.Physiologic and psychological symptoms experienced by adults with acute leukemia: an integrative literature review.Characteristics of palliative care consultation at an academic level one trauma center.Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.Symptom Management and Psychosocial Needs of Adults With Acute Myeloid Leukemia During Induction Treatment: A Pilot Study.Social Media: Support for Survivors and Young Adults With Cancer.Promoting evidence-based management of anemia in cancer patients: concurrent and discriminant validity of RESPOND, a web-based clinical guidance system based on the EORTC guidelines for supportive care in cancer.Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: Initial evidence from the RESPOND studyModeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) studyStriving to improve patient-reported outcomes for cancer survivors as the war wages onEmerging Models of Providing Oncology Palliative CarePsychosocial Experiences of Young Adults Diagnosed With Acute Leukemia During Hospitalization for Induction Chemotherapy TreatmentProgressive Assessment and Competency Evaluation Framework for Integrating Simulation in Nurse Practitioner Education
P50
Q30409900-3637A577-F4EA-41CE-A97B-222570774983Q35196705-D3636F19-A323-483C-8D29-E81A21F1BD91Q36243040-815956B2-EEB7-482C-ABAD-A95B9AC70501Q37641844-1A5F4673-35D9-4544-9880-8F30752D3FD7Q38207453-51CF8A57-30A6-4D84-840F-26131F87C3CFQ39424086-104525A8-44DA-4319-A810-291BBB1DA977Q44242768-5C99DBD4-CDF1-429C-9CA4-DCACAA485768Q45042500-7B00CEEB-BFC7-4E6D-B66A-5E075DAAD4EFQ47680065-281C886F-9508-4243-9089-548143A93B06Q51776715-1A3F5607-AFEE-4D99-8CCB-65B47D0AD670Q60685666-4377A679-4051-4855-89D2-3B64868F7E52Q60685667-FAD25107-B3F7-4A10-BEE8-5C4BF41CA570Q87118024-5418AF84-AF02-434D-967B-FB6A27E91153Q90904408-FAE5A1A4-F215-4F4C-A748-52ACE11AC7ECQ92101714-018EA910-A813-478E-A3F6-5CF86E76C4D3Q92180229-B048E9C2-8B44-4717-BDBF-CC3507CBF4B3
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Tara Albrecht
@en
Tara Albrecht
@nl
type
label
Tara Albrecht
@en
Tara Albrecht
@nl
prefLabel
Tara Albrecht
@en
Tara Albrecht
@nl
P31
P496
0000-0001-9687-3671